( CAMBRIDGE U.K. 2nd July 2007 - CeNeS ...)Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme,Health

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.

The paper reviews the preclinical and clinical data surrounding COMT and includes studies carried out by the world leading group based at the National Institute of Mental Health, Bethesda, Maryland, USA. The paper's authors collate recent developments in the analysis of the role of COMT genotypes and their involvement in cognitive deficits in schizophrenia and bipolar disorder. The paper supports the view that there is potential to use COMT inhibitors in ameliorating their cognitive deficits via an effect on prefrontal cortex brain function. As part of their conclusions the authors note, "The development of newer COMT inhibitors that can permeate the BBB (blood brain barrier) effectively and are devoid of serious adverse effects will allow expansion of the search for more specific, selective therapies for the treatment of cognitive disorders".

CeNeS has a leading position in the discovery of a novel series of COMT inhibitors with a programme currently focused on drugs for treatment of Parkinson's disease. In addition to this, the continuing progression of the scientific rationale for the potential use of COMT inhibitors in the treatment of schizophrenia and bipolar disorder places the CeNeS discovery programme in a good position in an exciting area of neuroscience.

Neil Clark, Chief Executive of CeNeS said: "CeNeS is excited about its discovery programme's potential to deliver improved drugs for the treatment of
'"/>